FLT3 - Wiki-MPM

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	SHC1	SHC adaptor protein 1	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signalling to RAS Signalling to RAS SHC1 events in EGFR signaling Tie2 Signaling Integrin signaling XBP1(S) activates chaperone genes Interleukin-3, Interleukin-5 and GM-CSF signaling Constitutive Signaling by EGFRvIII RAF/MAP kinase cascade Signal attenuation Insulin receptor signalling cascade Insulin receptor signalling cascade RET signaling Interleukin-15 signaling Interleukin-15 signaling Interleukin-2 signaling Erythropoietin activates RAS Erythropoietin activates RAS Interleukin receptor SHC signaling Constitutive Signaling by Overexpressed ERBB2 Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Signaling by CSF1 (M-CSF) in myeloid cells
Novel	SLA	Src like adaptor	Negative regulation of FLT3
Novel	SNRPA1	small nuclear ribonucleoprotein polypeptide A'	mRNA Splicing - Major Pathway Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
Novel	SOCS1	suppressor of cytokine signaling 1	Interleukin-7 signaling Regulation of KIT signaling MyD88:MAL(TIRAP) cascade initiated on plasma membrane Interleukin-4 and Interleukin-13 signaling Interferon gamma signaling Regulation of IFNG signaling Interferon alpha/beta signaling Regulation of IFNA/IFNB signaling Signaling by CSF3 (G-CSF) Inactivation of CSF3 (G-CSF) signaling Inactivation of CSF3 (G-CSF) signaling Growth hormone receptor signaling Antigen processing: Ubiquitination & Proteasome degradation
Novel	SRC	SRC proto-oncogene, non-receptor tyrosine kinase	Signaling by ERBB2 Nuclear signaling by ERBB4 Downregulation of ERBB4 signaling PIP3 activates AKT signaling GAB1 signalosome Downstream signal transduction Constitutive Signaling by Aberrant PI3K in Cancer Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins G alpha (s) signalling events G alpha (i) signalling events G alpha (i) signalling events DCC mediated attractive signaling DCC mediated attractive signaling Netrin mediated repulsion signals Regulation of commissural axon pathfinding by SLIT and ROBO RAF activation MAP2K and MAPK activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates PTK2 signaling InlA-mediated entry of Listeria monocytogenes into host cells Regulation of RUNX1 Expression and Activity RUNX2 regulates osteoblast differentiation Regulation of RUNX3 expression and activity Extra-nuclear estrogen signaling RHOU GTPase cycle Activated NTRK2 signals through FYN Activated NTRK3 signals through PI3K Activated NTRK3 signals through PI3K Long-term potentiation GPER1 signaling Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by CSF1 (M-CSF) in myeloid cells Degradation of CDH1	Dasatinib RU84687 RU79256 N6-Benzyl Adenosine-5'-Diphosphate RU85493 RU78262 Phosphonotyrosine Malonic acid RU83876 RU90395 RU79072 RU78783 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine PASBN 2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid PAS219 DPI59 RU82197 Phenylphosphate RU78300 RU79073 RU82209 ISO24 RU85053 RU78299 Oxalic Acid RU78191 Citric acid Paratoulene phosphate 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE Purvalanol A XL228 Tirbanibulin Bosutinib 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL PD-168393 [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile PP-121 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide Ponatinib Nintedanib Fostamatinib
Novel	UBE2L6	ubiquitin conjugating enzyme E2 L6	ISG15 antiviral mechanism DDX58/IFIH1-mediated induction of interferon-alpha/beta Termination of translesion DNA synthesis Negative regulators of DDX58/IFIH1 signaling Negative regulators of DDX58/IFIH1 signaling Amyloid fiber formation Antigen processing: Ubiquitination & Proteasome degradation RSV-host interactions PKR-mediated signaling Modulation of host responses by IFN-stimulated genes
	CBL	Cbl proto-oncogene	Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants		Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
	CBLB	Cbl proto-oncogene B	Antigen processing: Ubiquitination & Proteasome degradation
	CDK8	cyclin dependent kinase 8	PPARA activates gene expression NOTCH1 Intracellular Domain Regulates Transcription Generic Transcription Pathway SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants Transcriptional regulation of white adipocyte differentiation Transcriptional regulation of white adipocyte differentiation RSV-host interactions MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis	Alvocidib
	CTNNB1	catenin beta 1	Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade TCF dependent signaling in response to WNT Formation of the beta-catenin:TCF transactivating complex Formation of the beta-catenin:TCF transactivating complex LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Apoptotic cleavage of cell adhesion proteins Deactivation of the beta-catenin transactivating complex Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) Ca2+ pathway Adherens junctions interactions Binding of TCF/LEF:CTNNB1 to target gene promoters Disassembly of the destruction complex and recruitment of AXIN to the membrane Disassembly of the destruction complex and recruitment of AXIN to the membrane VEGFR2 mediated vascular permeability Myogenesis Myogenesis Signaling by GSK3beta mutants CTNNB1 S33 mutants aren't phosphorylated CTNNB1 S37 mutants aren't phosphorylated CTNNB1 S45 mutants aren't phosphorylated CTNNB1 T41 mutants aren't phosphorylated RHO GTPases activate IQGAPs Transcriptional Regulation by VENTX InlA-mediated entry of Listeria monocytogenes into host cells RUNX3 regulates WNT signaling Cardiogenesis Germ layer formation at gastrulation Regulation of CDH11 function Regulation of CDH11 function Regulation of CDH19 Expression and Function Regulation of CDH1 Function Degradation of CDH1 Regulation of CDH1 posttranslational processing and trafficking to plasma membrane Formation of paraxial mesoderm Formation of axial mesoderm Formation of definitive endoderm Somitogenesis Regulation of MITF-M-dependent genes involved in pigmentation Regulation of MITF-M-dependent genes involved in cell cycle and proliferation Formation of the nephric duct CDH11 homotypic and heterotypic interactions Specification of the neural plate border High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Transcriptional and post-translational regulation of MITF-M expression and activity Regulation of PD-L1(CD274) transcription	Urea	Pilomatricoma; Epithelioma calcificans of Malherbe Gastric cancer Hepatocellular carcinoma Thyroid cancer Colorectal cancer Endometrial Cancer
	ERBB2	erb-b2 receptor tyrosine kinase 2	Signaling by ERBB2 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Downregulation of ERBB2:ERBB3 signaling GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D induced cell migration and growth-cone collapse RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Constitutive Signaling by Overexpressed ERBB2 Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Mammary Stem Cells	Trastuzumab Lapatinib IGN311 Trastuzumab emtansine Varlitinib AV-412 Pertuzumab Afatinib Tucatinib Tesevatinib Fostamatinib Brigatinib Margetuximab Zanubrutinib	Breast cancer Cervical cancer Cholangiocarcinoma Pancreatic cancer Gastric cancer Ovarian cancer Choriocarcinoma Endometrial Cancer Bladder cancer
	FIZ1	FLT3 interacting zinc finger 1
	FLT1	fms related receptor tyrosine kinase 1	Neurophilin interactions with VEGF and VEGFR VEGF binds to VEGFR leading to receptor dimerization	Sorafenib Sunitinib Vatalanib TG-100801 OSI-930 Denibulin Linifanib IMC-1C11 Pazopanib Axitinib N-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide Regorafenib Lenvatinib Nintedanib Polaprezinc Foreskin fibroblast (neonatal) Tivozanib Fostamatinib Selpercatinib
	FLT3LG	fms related receptor tyrosine kinase 3 ligand	PI3K Cascade PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling FLT3 Signaling FLT3 Signaling STAT5 Activation Negative regulation of FLT3 FLT3 signaling through SRC family kinases FLT3 signaling through SRC family kinases FLT3 signaling by CBL mutants
	FMO1	flavin containing dimethylaniline monoxygenase 1	Degradation of cysteine and homocysteine FMO oxidises nucleophiles
	GPR12	G protein-coupled receptor 12		Cannabidiol Medical Cannabis Nabiximols
	GRB2	growth factor receptor bound protein 2	Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
	IKBKG	inhibitor of nuclear factor kappa B kinase regulatory subunit gamma	Activation of NF-kappaB in B cells Activation of NF-kappaB in B cells ER-Phagosome pathway NOD1/2 Signaling Pathway TICAM1, RIP1-mediated IKK complex recruitment RIP-mediated NFkB activation via ZBP1 Downstream TCR signaling FCERI mediated NF-kB activation TAK1-dependent IKK and NF-kappa-B activation activated TAK1 mediates p38 MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 SUMOylation of immune response proteins Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway IKBKB deficiency causes SCID IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) IkBA variant leads to EDA-ID CLEC7A (Dectin-1) signaling MAP3K8 (TPL2)-dependent MAPK1/3 activation Ub-specific processing proteases Ovarian tumor domain proteases Interleukin-1 signaling TRAF6 mediated NF-kB activation NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 IRAK1 recruits IKK complex IKK complex recruitment mediated by RIP1 SARS-CoV-2 activates/modulates innate and adaptive immune responses IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation Regulation of NF-kappa B signaling PKR-mediated signaling SLC15A4:TASL-dependent IRF5 activation Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Modulation of host responses by IFN-stimulated genes	AGRO100 Tarenflurbil	Incontinentia pigmenti Ectodermal dysplasia associated immunodeficiency (EDA-ID), including the following two diseases: NF-kappa-B essential modulator (NEMO) defect; Inhibitor of kappa-B (I-kappa-B) defect Osteoporosis, lymphedema, anhydrotic ectodermal dysplasia with immunodeficiency (OLEDAID); Ectodermal dysplasia, anhidrotic, with immunodeficiency, osteopetrosis, and lymphedema
	INPP5D	inositol polyphosphate-5-phosphatase D	Synthesis of PIPs at the plasma membrane Synthesis of IP3 and IP4 in the cytosol Downstream TCR signaling PECAM1 interactions Interleukin receptor SHC signaling Signaling by CSF1 (M-CSF) in myeloid cells
	NCK1	NCK adaptor protein 1	Downstream signal transduction Generation of second messenger molecules Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation Nephrin family interactions DCC mediated attractive signaling DCC mediated attractive signaling Activation of RAC1 VEGFA-VEGFR2 Pathway RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate WASPs and WAVEs RHOU GTPase cycle RHOV GTPase cycle FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis Potential therapeutics for SARS PKR-mediated signaling Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers

Search Results for: FLT3